AVADEL PHARMACEUTICALS(NASDAQ:AVDL) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to AVDL. AVDL was compared to 195 industry peers in the Pharmaceuticals industry. While AVDL seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, AVDL is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AVDL has reported negative net income.

In the past year AVDL has reported a negative cash flow from operations.

In the past 5 years AVDL reported 4 times negative net income.

In the past 5 years AVDL always reported negative operating cash flow.

1.2 Ratios

AVDL's Return On Assets of -45.86% is on the low side compared to the rest of the industry. AVDL is outperformed by 61.29% of its industry peers.

The Return On Equity of AVDL (-97.20%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-45.86%
ROE	-97.2%
ROIC	N/A

ROA(3y)-77.37%

ROA(5y)-50.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AVDL has a Gross Margin of 91.92%. This is amongst the best in the industry. AVDL outperforms 95.70% of its industry peers.

In the last couple of years the Gross Margin of AVDL has grown nicely.

AVDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	91.92%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.29%

GM growth 5Y3.15%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, AVDL has more shares outstanding

The number of shares outstanding for AVDL has been increased compared to 5 years ago.

There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

AVDL has an Altman-Z score of -1.49. This is a bad value and indicates that AVDL is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of AVDL (-1.49) is comparable to the rest of the industry.

AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.49

ROIC/WACCN/A

WACC7.07%

2.3 Liquidity

A Current Ratio of 2.97 indicates that AVDL has no problem at all paying its short term obligations.

AVDL has a Current ratio (2.97) which is in line with its industry peers.

A Quick Ratio of 2.60 indicates that AVDL has no problem at all paying its short term obligations.

AVDL has a Quick ratio (2.60) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.97
Quick Ratio	2.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.14%, which is quite impressive.

AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 1523.50%.

AVDL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.99% yearly.

EPS 1Y (TTM)65.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.68%

Revenue 1Y (TTM)1523.5%

Revenue growth 3Y7.78%

Revenue growth 5Y-22.99%

Sales Q2Q%613.22%

3.2 Future

Based on estimates for the next years, AVDL will show a very strong growth in Earnings Per Share. The EPS will grow by 27.72% on average per year.

Based on estimates for the next years, AVDL will show a very strong growth in Revenue. The Revenue will grow by 76.67% on average per year.

EPS Next Y74.6%

EPS Next 2Y42.93%

EPS Next 3Y33.73%

EPS Next 5Y27.72%

Revenue Next Year530.17%

Revenue Next 2Y206.75%

Revenue Next 3Y133.3%

Revenue Next 5Y76.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVDL. In the last year negative earnings were reported.

AVDL is valuated quite expensively with a Price/Forward Earnings ratio of 95.48.

AVDL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AVDL is cheaper than 73.66% of the companies in the same industry.

AVDL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 92.74, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	95.48

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

AVDL's earnings are expected to grow with 33.73% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.93%

EPS Next 3Y33.73%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AVDL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (2/5/2025, 10:46:06 AM)

8.25

+0.07 (+0.86%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Inst Owners79.53%

Inst Owner Change-0.25%

Ins Owners4.77%

Ins Owner Change0.88%

Market Cap747.26M

Analysts86.25

Price Target18.77 (127.52%)

Short Float %13.35%

Short Ratio8.26

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)29.25%

Min EPS beat(2)11.79%

Max EPS beat(2)46.72%

EPS beat(4)2

Avg EPS beat(4)1.83%

Min EPS beat(4)-41.55%

Max EPS beat(4)46.72%

EPS beat(8)2

Avg EPS beat(8)-25.46%

EPS beat(12)3

Avg EPS beat(12)-30.42%

EPS beat(16)6

Avg EPS beat(16)-19.03%

Revenue beat(2)2

Avg Revenue beat(2)4.65%

Min Revenue beat(2)0.9%

Max Revenue beat(2)8.41%

Revenue beat(4)4

Avg Revenue beat(4)4.23%

Min Revenue beat(4)0.9%

Max Revenue beat(4)8.41%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-21.03%

PT rev (3m)-25.2%

EPS NQ rev (1m)-30.18%

EPS NQ rev (3m)-223.55%

EPS NY rev (1m)-11.96%

EPS NY rev (3m)-9.48%

Revenue NQ rev (1m)-5.15%

Revenue NQ rev (3m)-6.53%

Revenue NY rev (1m)-1.32%

Revenue NY rev (3m)-2.78%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	95.48
P/S	5.41
P/FCF	N/A
P/OCF	N/A
P/B	10.01
P/tB	12.92
EV/EBITDA	N/A

EPS(TTM)-0.76

EYN/A

EPS(NY)0.09

Fwd EY1.05%

FCF(TTM)-0.91

FCFYN/A

OCF(TTM)-0.91

OCFYN/A

SpS1.53

BVpS0.82

TBVpS0.64

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-45.86%
ROE	-97.2%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	91.92%
FCFM	N/A

ROA(3y)-77.37%

ROA(5y)-50.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.29%

GM growth 5Y3.15%

F-Score4

Asset Turnover0.87

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.97
Quick Ratio	2.6
Altman-Z	-1.49

F-Score4

WACC7.07%

ROIC/WACCN/A

Cap/Depr(3y)17.05%

Cap/Depr(5y)11.62%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)65.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%92.68%

EPS Next Y74.6%

EPS Next 2Y42.93%

EPS Next 3Y33.73%

EPS Next 5Y27.72%

Revenue 1Y (TTM)1523.5%

Revenue growth 3Y7.78%

Revenue growth 5Y-22.99%

Sales Q2Q%613.22%

Revenue Next Year530.17%

Revenue Next 2Y206.75%

Revenue Next 3Y133.3%

Revenue Next 5Y76.67%

EBIT growth 1Y53%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year87.89%

EBIT Next 3Y49.37%

EBIT Next 5YN/A

FCF growth 1Y-5.95%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-6.93%

OCF growth 3YN/A

OCF growth 5YN/A

AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens